No intervention measures: No intervention measures, Using data obtained from the treatment of intracranial distal intracranial aneurysms with flow diverter, evaluate the effecy and safety of blood flow diverter for the endovascular treatment of distal intracranial aneurysms.
Study summary
Using data obtained from the treatment of intracranial distal intracranial aneurysms with flow diverter, evaluate the effecy and safety of blood flow diverter for the endovascular treatment of distal intracranial aneurysms.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age 18 to 80 years, any gender,Subjects who have accepted treatment with flow-diverting for distal intracranial aneurysms
2. Diagnosed with an intracranial aneurysm by CTA, MRA, or DSA, with the following features: a wide neck (≥4mm), or a dome-to-neck ratio \<2, saccular, fusiform aneurysms, recurrent saccular aneurysms, and dissecting aneurysms. Locations include: the Circle of Willis and it's distal branches such as the middle cerebral artery (MCA) M1-M3 segments, anterior cerebral artery (ACA) A1-A3 segments, posterior cerebral artery (PCA) P1-P2 segments, etc. (intracranial aneurysms of the Circle of Willis and it's distal vessels).
3. Subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed informed consent form
Exclusion Criteria:
1. Conditions that are not appropriate for stent delivery and deployment judged by investigators (severe stenosis of parent artery, severe tortuosity of parent artery, stent failing to reach the lesion, stent in the target lesion of parent artery, etc.)
2. mRS score ≥3
3. Heart, lung, liver and renal failure or other severe diseases (intracranial tumor, systemic infection, disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe psychosis, severe stenosis or occlusion of cerebral feeding artery, etc.)
4. Platelet count \<60×10\^9/L, known platelet dysfunction, or international normalized ratio (INR) \>1.5
5. Major surgery within 30 days before enrollment,or planned to undergo surgery within 360 days after enrollment
6. Known allergies or contraindications to anesthetics, anticoagulants, and antiplatelet drugs
7. Pregnant or breastfeeding women
8. Subject has participated in other clinical trials within 1 month before signing informed consent
9. Other conditions judged by the investigators as unsuitable for enrollment
Primary outcome measure(s)
Complete occlusion rate of aneurysm 12 months after surgery — 12 months after surgery
Trial sites (1)
Facility
City
Region
Status
First Affiliated Hospital of Zhejiang University
Hangzhou
Zhejiang
Recruiting
More First Affiliated Hospital of Zhejiang University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.